Safe switching from dasatinib to nilotinib after a 1-month off-drug period...
AbstractThe approval of two new tyrosine kinase (TK) inhibitors, nilotinib and dasatinib, has raised the issue of cross-intolerance. Evaluating the safety of interchanging TK inhibitors is particularly...
View ArticleClinical features of dasatinib-induced large granular lymphocytosis and...
AbstractDuring follow-up of leukocyte counts in 20 consecutive patients (age range 29–81 years) treated with dasatinib, 9 patients (7 chronic myeloid leukemia in chronic phase, 2 Philadelphia...
View ArticleEmpirical voriconazole therapy for febrile neutropenic patients with...
AbstractAn open-label, prospective, multicenter study was conducted between October 2006 and March 2010 to assess the efficacy and safety of intravenous voriconazole (VRCZ) as empirical therapy for...
View ArticleExpressional changes of genes and miRNA in common megakaryocyte-erythroid...
AbstractMyelodysplastic syndrome (MDS) is a stem cell tumor characterized by dysplastic features and ineffective hematopoiesis in the early phase and leukemic progression in the late phase. Speculating...
View ArticlePrognostic value of genetic mutations in adolescent and young adults with...
AbstractClinical outcomes and the genetic background of acute myeloid leukemia (AML) in adolescent and young adults (AYAs) are known to differ in younger children and older adults. To clarify the...
View ArticleClinical significance of ASXL2 and ZBTB7A mutations and C-terminally...
AbstractWe analyzed the clinical significance and genetic features of ASXL2 and ZBTB7A mutations, and the alternatively spliced isoform of the RUNX1-RUNX1T1 transcript, which is also called AML1-ETO9a...
View Article
